Literature DB >> 8105609

Characterization of human T-lymphotropic virus type I- and II-infected T-cell lines: antigenic, phenotypic, and genotypic analysis.

C S Dezzutti1, D L Rudolph, C R Roberts, R B Lal.   

Abstract

Eighteen long-term T-cell lines were established from peripheral blood mononuclear cells of individuals infected with human T-lymphotropic virus type I (HTLV-I) or II (HTLV-II). These cell lines (10 HTLV-I and 8 HTLV-II), representing diverse pathologic profiles and geographic regions, have been in culture for over 6 months and have constitutively produced p24gag antigen. Antigenic characterization of the cell lines by Western blot analysis demonstrated that all but one produced gag (p24) and env (gp46 or gp52) structural proteins; one HTLV-I-infected cell line exhibited an aberrant protein profile. Phenotypic analysis of the HTLV-infected cell lines demonstrated phenotypes consistent with activated T-cells (CD5+, CD25+, HLA-DR+). The HTLV-I-infected cell lines were predominantly CD4+ (IR, FS, A212, SP, 1657, 1742, 3669, 1996, and 3614), whereas EG was CD8+. The HTLV-II-infected cell lines were either CD4+ (H2A, Y17, G12.1), CD8+ (H1H, H2E, Y03, Y06), or both (H1B). Restriction map analysis and subtyping of the viral genomes demonstrated heterogeneity among these isolates. Of the HTLV-I-infected cell lines, six were subtype II, one was subtype III and, on the basis of additional restriction sites, another subtype, tentatively classified as subtype IV, could be identified for three of the HTLV-I-infected cell lines. Of the HTLV-II-infected cell lines, six were subtype HTLV-IIa and two were subtype HTLV-IIb. While the majority of the cell lines resemble the prototypic HTLV-I-infected (MT-2) and HTLV-II-infected (MoT) cell lines, the antigenic, phenotypic, and genotypic data collectively demonstrate heterogeneity among viral isolates representing diverse geographic regions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105609     DOI: 10.1016/0168-1702(93)90125-7

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

1.  RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells.

Authors:  Hsin-Ching Lin; Peter J Simon; Riza M Ysla; Steven L Zeichner; Gary Brewer; Arnold B Rabson
Journal:  Virology       Date:  2017-05-04       Impact factor: 3.616

2.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Infection with human T-lymphotropic virus types I and II results in alterations of cellular receptors, including the up-modulation of T-cell counterreceptors CD40, CD54, and CD80 (B7-1).

Authors:  C S Dezzutti; D L Rudolph; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

4.  Activation of human T-cell leukemia virus type 1 tax gene expression in chronically infected T cells.

Authors:  H C Lin; C S Dezzutti; R B Lal; A B Rabson
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

5.  Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

Authors:  Michael S Mitchell; Ellen T Bodine; Shawn Hill; Gerald Princler; Patricia Lloyd; Hiroaki Mitsuya; Masao Matsuoka; David Derse
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 6.  Cell surface markers in HTLV-1 pathogenesis.

Authors:  Andrea K Kress; Ralph Grassmann; Bernhard Fleckenstein
Journal:  Viruses       Date:  2011-08-16       Impact factor: 5.048

7.  Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.

Authors:  Machiko Nomura; Takashi Ohashi; Keiko Nishikawa; Hironori Nishitsuji; Kiyoshi Kurihara; Atsuhiko Hasegawa; Rika A Furuta; Jun-ichi Fujisawa; Yuetsu Tanaka; Shino Hanabuchi; Nanae Harashima; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.